Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma

Plasticity in binding confers selectivity in ligand-induced protein degradation

(2018) Radosław P. Nowak et al.   Nature Chemical Biology

Ixazomib for the treatment of multiple myeloma

(2018) Paul G. Richardson et al.   EXPERT OPINION ON PHARMACOTHERAPY

Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targets

(2017) Xiuxiu Lu et al.   Nature Communications

Therapeutic Advances in Relapsed or Refractory Multiple Myeloma

(2017) Kenneth C. Anderson   Journal of the National Comprehensive Cancer Network

Small-Molecule PROTACS: New Approaches to Protein Degradation

(2016) Momar Toure et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

SPLINTS: small-molecule protein ligand interface stabilizers

(2016) Eric S Fischer et al.   CURRENT OPINION IN STRUCTURAL BIOLOGY

Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma

(2016) Y Song et al.   LEUKEMIA

Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging

(2015) Jeffrey L. Gustafson et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

(2015) Jing Lu et al.   CHEMISTRY & BIOLOGY

ADRM1-amplified metastasis gene in gastric cancer

(2015) Marlena S. Fejzo et al.   GENES CHROMOSOMES & CANCER

A Reversible and Highly Selective Inhibitor of the Proteasomal Ubiquitin Receptor Rpn13 Is Toxic to Multiple Myeloma Cells

(2015) Darci J. Trader et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Structural Plasticity Allows UCH37 to Be Primed by RPN13 or Locked Down by INO80G

(2015) Xiang Chen et al.   MOLECULAR CELL

Phthalimide conjugation as a strategy for in vivo target protein degradation

(2015) G. E. Winter et al.   SCIENCE

A bis-Benzylidine Piperidone Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 as a Therapy for Cancer

(2013) Ravi K. Anchoori et al.   CANCER CELL

In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells

(2013) D. Chauhan et al.   CLINICAL CANCER RESEARCH

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

(2013) G. Lu et al.   SCIENCE

Ubiquitin-Binding Proteins: Decoders of Ubiquitin-Mediated Cellular Functions

(2012) Koraljka Husnjak et al.   Annual Review of Biochemistry

Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells

(2012) Z. Tian et al.   BLOOD

A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance

(2012) Dharminder Chauhan et al.   CANCER CELL

Identification of a Primary Target of Thalidomide Teratogenicity

(2010) T. Ito et al.   SCIENCE

Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target

(2009) Dharminder Chauhan et al.   CANCER CELL

Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells

(2009) Chen   ONCOLOGY REPORTS

Comprehensive analysis of 20q13 genes in ovarian cancer identifiesADRM1as amplification target

(2008) Marlena S. Fejzo et al.   GENES CHROMOSOMES & CANCER

Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression

(2008) B Carvalho et al.   GUT

Ubiquitin docking at the proteasome through a novel pleckstrin-homology domain interaction

(2008) Patrick Schreiner et al.   NATURE